Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.33 |
| ▸ | BAD | Q92934 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 3/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1835087 | 0.94 | PARP1 (0.40) | PARP1TSHRBCL2L1BADHTR1A | |
| SCHEMBL16361841 | 0.89 | DRD1 (0.42) | PARP1TSHR | |
| SCHEMBL1835160 | 0.89 | DRD1 (0.39) | PARP1TSHR | |
| SCHEMBL1833547 | 0.86 | PARP1 (0.50) | PARP1HTR1A | |
| SCHEMBL17868301 | 0.85 | CTNNB1 (0.34) | — | |
| SCHEMBL1836407 | 0.83 | DRD1 (0.40) | PARP1TSHRHTR1A | |
| SCHEMBL16361843 | 0.83 | DRD1 (0.43) | PARP1TSHRHTR1A | |
| SCHEMBL16323362 | 0.80 | CTNNB1 (0.37) | CA1CA9 | |
| SCHEMBL16361854 | 0.80 | CTNNB1 (0.37) | CA1CA9 | |
| SCHEMBL17875571 | 0.79 | PARP1 (0.44) | PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2321244-B1 | IMPROVED PROCESS FOR TELOMERIZATION OF BUTADIENE | DOW GLOBAL TECHNOLOGIES LLC (US) | 2016-12-21 | — | — | EP | disclosed |
| US-8558030-B2 | Process for telomerization of butadiene | DOW GLOBAL TECHNOLOGIES LLC (US) | 2013-10-15 | — | — | US | disclosed |
| US-20110137086-A1 | PROCESS FOR TELOMERIZATION OF BUTADIENE | Dow Global Technologies LLC (Formerly known as Dow Global Technologies Inc.) (US) | 2011-06-09 | — | — | US | disclosed |
| EP-2321244-A2 | AN IMPROVED PROCESS FOR TELOMERIZATION OF BUTADIENE | Dow Global Technologies LLC (US) | 2011-05-18 | — | — | EP | disclosed |
| WO-2010019360-A2 | AN IMPROVED PROCESS FOR TELOMERIZATION OF BUTADIENE | DOW GLOBAL TECHNOLOGIES INC. (US) | 2010-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110137086-A1 | PROCESS FOR TELOMERIZATION OF BUTADIENE | HRH3, HRH4, TELO2 | PARP1 389/4885TSHR 1049/4885BCL2L1 1521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.